IL33 and chronic obstructive pulmonary disease: Conversely, a recent clinical trial of an IL-33 blocking antibody in COPD patients found that the improvements in lung function and exacerbation rate observed in the cohort as a whole were mainly amongst ex-smokers, with no clinical benefit to current smokers (Rabe et al., 2021).